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• Increased	maternal	and	perinatal	morbidity	and	mortality	(Black et al., 









































































































































































Biomarker	 Origin	 EE	domain	assessed	 Comment	
LPS	 Plasma	 Intestinal	permeability;	microbial	translocation	 Bacterial	product;	detection	in	blood	implies	translocation	
Anti-LPS	IgG	 Plasma	 Microbial	translocation	 Quantifies	host	adaptive	response	to	systemic	LPS	
sCD14	 Plasma	 Systemic	immune	activation;	microbial	translocation	 Marker	of	innate	immune	activation;	secreted	by	activated	monocytes	/	macrophages	in	response	to	LPS	
LBP	 Plasma	 Systemic	immune	activation;	microbial	translocation	 Acute	phase	reactant	in	response	to	systemic	LPS;	agonist	for	TLR	signalling	and	monocyte	activation	
MBL	 Plasma	 Systemic	immune	activation;	microbial	translocation	 Acute	phase	protein;	binds	to	bacterial	carbohydrate	residues	
CRP	 Plasma	 Systemic	immune	activation	 Non-specific	marker	of	systemic	immune	activation	
Citrulline	 Plasma	 Absorptive	capacity	 Biproduct	of	enterocyte	glutamine	meta-bolism;	used	as	a	marker	of	enterocyte	mass	
iFABP	 Plasma	 Intestinal	barrier	damage	 Released	from	damaged	enterocytes;	higher	levels	observed	in	EE	than	in	coeliac	disease	
α1AT	 Stool	 Intestinal	permeability	 Serum	protein	detectable	in	stool	from	abnormally	permeable	intestine	
MPO	 Stool	 Intestinal	inflammation	 Secreted	by	activated	neutrophils	/	mono-cytes	/	macrophages	in	inflamed	intestine	
Calprotectin	 Stool	 Intestinal	inflammation	 Secreted	by	activated	neutrophils	/	mono-cytes	/	macrophages	in	inflamed	intestine	























aetiology	 Diagnosis	 Intestinal	distribution	Populations	affected	 Villus				atrophy	 Mucosal	inflammation	Barrier	defect	 Systemic	inflammation	Malabsorption	Management	Mortality	
EE	 Undernutrition;	dysbiosis	 E;	H;	F	 DJ	 LMIC	 +	/	+++	 ++	 +	 +	 +	 ?	 (–)	
Kwashiorkor	 Undernutrition;	dysbiosis	 C	 DJI	 LMIC	 +	/	+++	 ++	 ++	 ++	 ++	 Nutrition;	antibiotics	 +++	
Marasmus	 Undernutrition	 C	 DJI	 LMIC	 +	/	+++	 ++	 +	 +	 +	 Nutrition	 ++	
Coeliac	
disease	
Cross–reactivity	to	dietary	gluten	 S;	H	 DJ	 Caucasian	 +	/	+++	 ++	 –	 –	 ++	 Dietary	restriction	 –	
Tropical	
sprue	
Infectious	 C	 D	 Caribbean;	South	Asia	 +	/	+++	 ++	 +/–	 –	 ++	 Antibiotics;	folate	 –	
Crohn’s	 Dysregulated	immunity;	dysbiosis	 E;	C;	H	 (J)I	 Western	 +	 +++	 ++	 ++	 +	 Nutrition;	immune-modulation	 –	
Helminths	
and	Giardia	




Inflammatory	/	immune	mediated	 M;	S	 DJI	 Worldwide	 +	 ++	 +	 +	 +	 Antivirals	 –	
HIV–AIDS	 Infectious	 C;	M;	H;	S	 DJI	 Predom.	LMIC	 +	/	+++	 +++	 +++	 +++	 +++	 Antivirals	/	antimicrobials	 +++	










































































Protein	 Name	 Complex	 Function	
MTOR	 Mechanistic	target	of	rapamycin	 Both	 Ser	/	Thr	kinase;	finally	activated	by	disinhibition	of	TSC	signalling	
DEPTOR	 DEP	domain-containing	MTOR-interacting	protein	 Both	 MTOR	inhibitor;	degrades	on	MTOR	activation	
mLST8	 Mammalian	lethal	with	SEC13	protein	8	 Both	 Unknown	
PRAS40	 40	kDa	Proline-rich	AKT	substrate	 MTORC1	 MTORC1	inhibitor;	mediates	AKT	signalling	
Raptor	 Regulatory-associated	protein	of	MTOR	 MTORC1	 Scaffold	protein	with	regulatory	roles;	mediates	AMPK	signalling;	binds	activated	RAG	GTPase/Ragulator	complex	
mSin1	 Mammalian	stress-activated	protein	kinase-interacting	protein	1	 MTORC2	 Scaffold	protein	
Rictor	 Rapamycin-insensitive	companion	of	MTOR	 MTORC2	 Scaffold	protein,	promotes	AKT	signalling	










molecular functions of these protein complexes are still
emerging but are influence by the presence or absence of
specific amino acids, such as leucine and arginine [8!!
,9!!], which promote the accumulation of Rag heterodi-
mers containing GTP-bound RagA/B in complex with
GDP-bound RagC/D. In this amino acid-stimulated state
the Rag heterodimer, bound to the Ragulator, serves as a
docking site for mTORC1 at the lysosome, thereby
facilitating its subsequent activation by the Rheb GTPase
[4].
A subpopulation of Rheb (Rheb1 and Rheb2/Rhebl1)
resides at the lysosomal surface and, in the GTP-bound
state, is essential for mTORC1 activation [10,11!!]. The
only established regulator of Rheb is a GTPase-activating
protein (GAP) complex comprised of the tuberous scle-
rosis complex (TSC) proteins TSC1 and TSC2 and the
TBC domain protein TBC1D7, referred to as the TSC
complex [2,12]. Within this complex, TSC1 scaffolds
TSC2 and TBC1D7 together and stabilizes them. While
the molecular function of TBC1D7 is unknown, TSC2
possesses the GAP activity toward Rheb and is regulated
by multi-site phosphorylation downstream of several pro-
tein kinase signaling pathways. In this manner, the TSC
complex integrates signals from growth factor pathways,
such as the PI3K–Akt and Ras–Erk pathways, and stress
response kinases, such AMPK, which is activated in
response to cellular energy depletion. Pro-growth signals
from growth factor and nutrient sensing pathways inhibit
the TSC complex to promote the accumulation of Rheb-
GTP and its activation of mTORC1, while growth-sup-
pressing signals, including growth factor withdrawal,
nutrient depletion or cellular stress, activate the TSC
complex to decrease Rheb-GTP levels and shut down
mTORC1 signaling.
Growth factor signaling through the PI3K–Akt pathway,
and perhaps other signals, regulate mTORC1 by influ-
encing co-localization of the TSC complex with Rheb at
the lysosomal surface [11!!,13]. The Akt-mediated phos-
phorylation of TSC2 results in immediate release of the
TSC complex from Rheb, allowing Rheb to become GTP
loaded and activates mTORC1 [11!!]. While signals
relaying the presence of exogenous growth factors and
sufficient intracellular nutrients and energy are both
required for full activation of mTORC1, nutrient and
energy signals from within the cell are dominantly
required for mTORC1 to perceive signals propagated































Current Opinion in Cell Biology
mTORC1 is a molecular switch between catabolic and anabolic processes. (a) A standard metabolic cycle. Anabolic processes convert nutrients
and energy into macromolecules, and catabolic processes can convert macromolecules into their nutrient components and energy. (b) Through
the sensing of exogenous growth factors and endogenous nutrients and energy, mTORC1 serves to tip the metabolic balance away from catabolic
processes and toward anabolic processes to produce biomass.

































































CD4+		 TH1	TH2	TH17	generation	 Treg	generation	 (Waickman	and	Powell,	2012)	
CD8+		 Teff		generation	 Tmem	generation	 (Araki	et	al.,	2009a)	
B	 	 Reduced	plasma	cell	generation	and	antibody	secretion	 (Jones	et	al.,	2016)	
NK	 Effector	functions	 Anergy	 (Donnelly	et	al.,	2014)	
Dendritic	cells	 Activation	 Anergy	 (Krawczyk	et	al.,	2010)	
Monocytes	 Trained	immunity	 Impaired	survival	and	antigen	response	 (Cheng	et	al.,	2014)	































































1.8.1.1 Aims	(primary	outcomes)	1. To	assess	the	effect	of	supplementation	on	small	intestinal	histology	as	assessed	by	morphometry.	2. To	assess	the	effect	of	supplementation	on	intestinal	barrier	dysfunction	as	assessed	by	confocal	laser	endomicroscopy.	3. To	assess	the	effect	of	supplementation	on	lamina	propria	CD4+	T	cell	MTORC1	signalling.		
1.8.1.2 Aims	(secondary	outcomes)	1. To	investigate	the	effect	of	supplementation	on	plasma	markers	of	microbial	translocation	and	immune	activation	(sCD14,	CRP,	LPS).	2. To	investigate	the	effect	of	supplementation	on	metabonomic	profile.	3. To	investigate	the	effect	of	supplementation	on	anthropometry	and	body	composition.		













































































Week	 -4	to	0	 0	 4	 8	 12	 16-19	 16-20	
History	&	physical	
examination	
X       
HIV	test	 X       
Stool	culture	 X       
CLE	&	duodenal	biopsies	  X    X  
Blood,	urine,	saliva,	
stool	samples	
 X    X  
Body	composition	&	
anthropometrics	
 X    X  
Compliance	&	AE	
monitoring	
  X X X  X 
Supplement	
administration	
















































Vitamin	A	RE	(µg)	 800	 1600	 800	 2	
Vitamin	D3	(µg)	 10	 20	 5	 4	
Vitamin	E	α-TE	(mg)	 40	 80	 12	 6.66	
Vitamin	K	(μg)	 70	 140	 75	 1.86	
Vitamin	C	(mg)	 150	 300	 80	 3.76	
Thiamin	(mg)	 18	 36	 1.1	 32.72	
Riboflavin	(mg)	 6	 12	 1.4	 8.58	
Niacin	NE	(mg)	 27	 54	 16	 3.38	
Vitamin	B6	(mg)	 10	 20	 1.4	 14.28	
Folic	acid	(μg)	 400	 800	 200	 4	
Vitamin	B12	(μg)	 14	 28	 2.5	 11.2	
Pantothenic	acid	(mg)	 20	 40	 6	 6.66	
Iron	(mg)	 8	 16	 14	 1.14	
Magnesium	(mg)	 60	 120	 375	 0.32	
Zinc	(mg)	 15	 30	 10	 3	
Iodine	(μg)	 200	 400	 150	 2.66	
Copper	(mg)	 500	 1000	 1	 1	
Manganese	(mg)	 4	 8	 2	 4	
Selenium	(μg)	 180	 360	 55	 6.54	
Chromium	(μg)	 100	 200	 40	 5	
L-Cystine	(mg)	 40	 80	 N/A	 N/A	
L-Carnitine	(mg)	 30	 60	 N/A	 N/A	
































































































































































































































































	 Immunophenotype	 Conjugate	 Determination	of	positivity	
Activated	MTORC1	 p4EBP1(T36/T45)+	 PE	 Unstimulated	control	
Activated	cell	 HLA-DR+		 APC	 IgG2A	κ	isotype	control		
T	lymphocyte	 CD3+	 APC-Cy7	 Bimodal	
CD4+	lymphocyte	 CD3+	CD4+	 PerCP-Cy5.5	 Bimodal	





















Phospho-4EBP1(T36/T45)	/	PE	 1μl	 1μl	 Cell	Signaling	Technology;	2855	
CD3	/	APC-Cy7	 2μl	 2μl	 SK7;	BD	Biosciences;	557832	
CD4	/	PerCP-Cy5.5	 1μl	 1μl	 RPA-T4;	BD	Biosciences;	560650	
HLA-DR	/	APC	 2μl	 –	 G46-6;	BD	Biosciences;	559866	



















	 Immunophenotype	 Conjugate	 Determination	of	positivity	
TH1		 CD3+	CD4+	TBET+	 PE-Cy7	 IgG1	κ	isotype	control	
Activated	cell	 HLA-DR+		 APC	 IgG2A	κ	isotype	control	
T	lymphocyte	 CD3+		 APC-Cy7	 Bimodal	
CD4+	lymphocyte	 CD3+	CD4+	 PerCP-Cy5.5	 Bimodal	
Table	3.4.	Antibody	panel	for	TH1	assay.		
 128 
	 TH1	assay	 Control	 Clone;	manufacturer;	cat.	#	
TBET	/	PE-Cy7	 1μl	 –	 4B10;	Biolegend,	644824	
IgG1	κ	isotype	/	PE-Cy7	 –	 1μl	 MOPC-21;	Biolegend;	400126	
CD3	/	APC-Cy7	 2μl	 2μl	 SK7;	BD	Biosciences;	557832	
CD4	/	PerCP-Cy5.5	 1μl	 1μl	 RPA-T4;	BD	Biosciences;	560650	
HLA-DR	/	APC	 2μl	 –	 G46-6;	BD	Biosciences;	559866	































Marker	 Manufacturer	 Cat.	#	 Dilution	 Standards	range	
CRP	 R&D	Systems	 DCRP00	 1/1000	 0-50ng/ml	
sCD14	 R&D	Systems	 DC140	 1/400	 0-16ng/ml	




































































Amino	acids	(n=52)	 Placebo	(n=50)	 Micronutrients	(n=52)	 Placebo	(n=50)	
Age,	years	 32	(22-45)	 39	(23-45)	 35	(24-45)	 34	(22-45)	
Sex,	M:F	 19:33	 14:36	 17:35	 16:34	
HIV	positive,	n	(%)	 15	(29)	 15	(30)	 16	(31)	 14	(28)	
	
Peripheral	CD4	count	 548	(305-613)	 554	(417-790)	 472	(327-697)	 582	(467-740)	
Height,	cm	 Male	 168	(165	–	174)	 168	(164	–	172)	 166	(165	–	174)	 171	(165	–	173)	
Female	 157	(153	–	161)	 158	(154	–	161)	 157	(153	–	161)	 157	(154	–	161)	
Body	mass	index,	kg.m-2		 Male	 19.9	(19.0	–	20.2)	 20.6	(19.6	–	25.7)	 20.1	(19.1	–	23.3)	 19.8	(19.1	–	20.5)	
Female	 24.6	(21.2	–	25.8)	 25.0	(20.7	–	29.0)	 23.5	(20.2	–	26.9)	 25.1	(20.5	–	28.3)	
Body	fat	by	ADP,	%	 Male	 16.9	(14.7	–	19.0)	 11.4	(7.8	–	25.8)	 14.3	(10.7	–	18.3)	 14.8	(11.0	–	17.7)	
Female	 33.7	(24.5	–	35.8)	 36.1	(27.6	–	44.1)	 34.0	(24.1	–	40.5)	 34.3	(27.7	–	39.3)	
Grip	strength,	kg	 Male	 39.5	(36.2	–	41.9)	 39.1	(36.1	–	42.2)	 40.8	(34.9	–	45.8)	 39.1	(36.2	–	41.6)	
Female	 27.2	(23.4	–	31.3)		 28.1	(25.9	–	33.0)	 28.6	(26.4	–	34.7)	 26.9	(24.2	–	32.2)	
Completed	primary	education,	%	 36	 54	 42	 48	
Household	Hygiene	Score	a,	(0-10)	 6	(5-7)	 6	(5-7)	 6	(5-7)	 6	(5-7)	
Household	electricity,	%	 71.2	 66	 69.2	 68	
Routinely	boil	water	b,	%	 7.6	 6	 5.7	 8	
Routinely	chlorinate	water	b,	%	 17.3	 30	 19.2	 28	






	 Amino	acids	(n=42)	 Placebo	(n=42)	 Micronutrients	(n=41)	 Placebo	(n=43)	
Age,	years	 35	(28-46)	 42	(24-51)	 40	(21-30)	 40	(30-46)	
Sex,	M:F	 16:26	 10:32	 11:30	 15:28	
HIV	seropositive,	n	(%)	 13	(31)	 14	(33)	 16	(38)	 11	(26)	
	 Peripheral	CD4	count	 510	(268	–	683)	 621	(422	–	800)	 472	(305	–	750)	 602	(387	–	827)	
Height,	cm	 Male	 169	(166	–	174)	 171	(165	–	172)	 166	(165	–	173)	 171	(166	–	174)	
Female	 157	(154	–	162)	 158	(154	–	161)	 157	(153	–	161)	 157	(154	–	161)	
Body	mass	index,	kg.m-2	 Male	 19.9	(19.0	–	20.2)	 20.6	(19.6	–	25.7)	 20.6	(20.0	–	25.4)	 19.7	(19.1	–	20.2)	
Female	 24.6	(21.2	–	25.8)	 25.0	(20.7	–	29.0)	 23.5	(20.1	–	27.4)	 25.1	(21.4	–	27.9)	
Body	fat	by	ADP,	%	 Male	 16.9	(14.7	–	19.0)	 11.4	(7.8	–	25.8)	 17.5	(11.6	–	24.1)	 15.8	(11.0	–	18.6)	
Female	 33.7	(24.5	–	35.8)	 36.1	(27.6	–	44.1)	 34.3	(23.9	–	40.2)	 34.5	(27.9	–	39.0)	
Grip	strength,	kg	 Male	 39.5	(36.2	–	41.9)	 39.1	(36.1	–	42.2)	 40.2	(35.7	–	46.6)	 39.2	(36.4	–	41.7)	
Female	 27.2	(23.4	–	31.3)	 28.1	(25.9	–	33.0)	 28.7	(26.5	–	34.0)	 26.7	(23.6	–	31.6)	
Completed	primary	education,	%	 35.7	 51.2	 40.5	 46.5	
Household	hygiene	score	a,	0-10	 6	(5	–	7)	 6	(5	–	6)	 6	(5	–	6.5)	 5	(5	–	8)	
Household	electricity,	%	 69.1	 65.1	 69.1	 65.1	
Routinely	boil	water	b,	%	 9.5	 4.7	 7.0	 7.1	
Routinely	chlorinate	water	b,	%	 14.3	 34.9	 19.1	 30.2	





















VH	(μm)	 185	(154-217)	 218	(201-250)	 202	(181-252)	 206	(170-235)	
CD	(μm)	 163	(141-196)	 163	(150-198)	 157	(135-194)	 174	(152-199)	
VW	(μm)	 230	(210-263)	 222	(197-268)	 221	(202-253)	 230	205-267)	
VP	(μm)	per	100μm	
muscularis	mucosae	
865	(702-1030)	 987	(868-1134)	 931	(788-1072)	 913	(772-1090)	
VA	(μm2)	per	100μm	
muscularis	mucosae	





Change	in:	 AA	(n=26)	 Placebo	(n=23)	 P	
Villus	Height	(μm)		 2.5	(59)	 -32.0	(57)	 0.04	
Crypt	Depth	(μm)	 -13.3	(39)	 -31.1	(45)	 0.2	












Change	in:	 MM	(n=26)	 Placebo	(n=23)	 P	
Villus	Height	(μm)		 -19.5	(62)	 -8.6	(60)	 0.5	
Crypt	Depth	(μm)	 -25.5	(43)	 -18.3	(43)	 0.6	

























	 AA	 Placebo	 MM	 Placebo	
Median	(IQR)	fields	
with	dysfunction,	%	













	 AA	(n=14)	 Placebo	(n=23)	 MM	(n=18)	 Placebo	(n=19)	
%	p4EBP1	positive	 47.9	(41.1	–	58.3)	 60.0	(44.6	–	67.0)	 58.1		(46.8	–	65.1)	 48.3		(32.9	–	61.9)	
Table	4.9.	Proportion	of	CD3+	CD4+	lamina	propria	lymphocytes	responding	to	in	vitro	nutrient	
stimulation	at	baseline.		
Change	in:	 AA	 Placebo	 P		 MM	 Placebo	 P		
Basal	p4EBP1	MFI	 -152	(56)	 -125	(85)	 1.0	 -121	(67)	 -150	(81)	 0.3	
Max.	p4EBP1	MFI	 -288	(128)	 -276	(126)	 0.8	 -281	(114)	 -282	(138)	 0.9	
%	p4EBP1	positive	 -9.0	(18.5)	 -10.2	(19.1)	 0.9	 -15.0	(13.5)	 -4.8	(21.5)	 0.2	
Table	4.10.	Change	in	lamina	propria	CD4+	MTORC1	signalling	according	to	intervention.			Examining	for	main	effects	and	interactions	by	univariate	ANOVA	confirmed	there	were	no	main	or	interaction	effects	for	the	interventions	on	the	change	in	phospho-4EBP1	positivity	(P	0.6	for	AA;	P	0.14	for	MM;	P	0.5	for	interaction),	basal	MTORC1	activation	(P	0.3	for	AA;	P	0.3	for	MM;	P	0.5	for	interaction),	or	maximal	MTORC1	activation	(P	0.8	for	AA;	P	0.9	for	MM;	P	0.4	for	interaction).	The	Shapiro-Wilk	test	confirmed	normality	for	these	outcomes.	The	proportion	of	MTORC1	responsive	cells	was	correlated	with	maximal	MTORC1	activity,	but	not	with	basal	activity.	Basal	and	maximal	MTORC1	activity	was	positively	correlated	(Table	4.11).	These	correlations	were	stronger	and	more	significant	across	all	treatment	groups	as	a	whole	after	the	intervention	period	(Table	4.11;	overall	correlations	across	treatment	groups	shown).		
	 Pre-supplementation	 Post-supplementation	
	 ρ		 P		 ρ		 P		
%	responsive	v.	basal	activity	 -0.2	 0.3	 0.1	 0.6	
%	responsive	v.	max.	activity	 0.4	 0.01	 0.5	 0.001	











	 HIV	negative	(n=57)	 HIV	positive	(n=27)	 P		
Age	 34.4	(22.0	–	47.0)	 41.0	(35.0	–	50.0)	 0.02	
Sex,	M:F	 22:35	 4:23	 0.02	a	
Height,	cm	 Male	 167	(165	–	172)	 173	(171	–	174)	 0.08	
Female	 156	(153	–	161)	 159	(156	–	162)	 0.09	
Body	mass	index,	kg.m-2	 Male	 20.1	(19.2	–	21.2)	 19.9	(19.3	–	24.4)	 0.8	
Female	 25.0	(22.2	–	28.4)	 23.3	(20.0	–	27.6)	 0.08	
Fat	%	by	ADP	 Male	 15.9	(11.0	–	18.0)	 20.0	(14.5	–	30.0)	 0.2	
Female	 34.2	(27.7	–	41.1)	 34.3	(24.3	–	38.8)	 0.3	
Grip	strength,	kg	 Male	 39.4	(36.2	–	42.7)	 38.0	(34.8	–	41.3)	 0.5	
Female	 27.6	(24.2	–	33.2)	 28.3	(24.2	–	30.5)	 0.9	
Completed	primary	education,	%	 44.8	 40.7	 0.7	a	
Household	hygiene	score,	0-10	 6	(5	–	7)	 6	(5	–	6)	 0.15	
Household	electricity,	%	 72.4	 55.6	 0.1	b	
Routinely	boil	water	 2/57	 4/27	 0.08	a	
Routinely	chlorinate	water	 14/57	 7/27	 1	a	





	 HIV	negative	n	 HIV	positive	n	 P	
VH,	μm	 42	 200	(168	–	242)	 19	 212	(190	–	249)	 0.5	
CD,	μm	 42	 166	(139	–	197)	 19	 163	(152	–	199)	 0.9	
VW,	μm	 42	 229	(204	–	256)	 19	 223	(199	–	289)	 1	
VA	per	unit	MM	 42	 17900	(13600	–	21200)	 19	 18300	(15400	–	21300)	 0.9	
VP	per	unit	MM	 42	 511	(423	–	676)	 19	 512	(457	–	590)	 1	
%	CD4+	p4EBP1+	 33	 49.5	(39.7	–	65.0)	 11	 57.1	(48.6	–	77.4)	 0.4	
Basal	p4EBP1	MFI	 33	 265	(239	–	318)	 11	 300	(261	–	349)	 0.4	
Max.	p4EBP1	MFI	 33	 502	(434	–	563)	 11	 510	(394	–	597)	 1	






























Adverse	event	 Placebo	 AA	 Placebo	 MM	
Abdominal	fullness	
	 1	 1	 	
Abdominal	pain	 8	 3	 4	 7	
Accidental	ingestion	of	sachet	
	 1	 1	 	
Anorexia	
	 2	 1	 1	
Backache	 5	 4	 5	 4	
Body	pains	 3	 1	 2	 2	
Body	weakness	
	 3	 	 3	
Chest	pain	 1	 	 	 1	
Cough	 4	 1	 2	 3	
Cough	requiring	oral	antibiotics	 6	 6	 4	 8	
Diarrhoea	(severe)*	 5	 2	 2	 5	
Diarrhoea	(uncomplicated)	 5	 8	 9	 4	
Dizziness	 5	 2	 3	 4	
Dysmenorrhoea	
	 1	 	 1	
Febrile	illness	requiring	oral	antibiotics	 1	 1	 	 2	
Feet	swelling	 1	 	 1	 	
Fever	 1	 1	 1	 1	
Headache	 10	 13	 8	 15	
Heart	palpitations	 2	 	 1	 1	
Herpes	zoster	
	 1	 	 1	
Hunger	 6	 15	 8	 13	
Incomplete	spontaneous	abortion	 1	 	 1	 	
Joint	pains	 4	 3	 4	 3	
Malaise	 1	 	 	 1	
Malaria	(self-diagnosed)	
	 1	 1	 	
Malarial	illness**	 3	 6	 5	 4	
Nausea	 5	 10	 6	 9	
Odynophagia	
	 1	 1	 	
Oversedation	at	endoscopy***	 1	 	 1	 	
Painful	legs	 2	 3	 3	 2	
Phlebitis	at	sedative	injection	site	 2	 1	 1	 2	
Prolonged	menstrual	bleeding	 1	 	 1	 	
Rash	 1	 	 	 1	
Reduced	mobility	 1	 	 	 1	
Sleepiness	
	 2	 	 2	
Sneezing	 2	 4	 2	 4	
Sore	mouth	 1	 	 1	 	
Sore	throat	 1	 	 	 1	
Sore	throat	requiring	oral	antibiotics	 1	 1	 1	 1	
Toothache	
	 1	 1	 	
Toothache	requiring	oral	antibiotics	 1	 	 	 1	
Borborygmi	
	 1	 1	 	
Vomiting	 6	 6	 5	 7	
Weakness	 1	 1	 1	 1	
Weight	loss	
	 1	 	 1	

















	 CD4+		 CD8+		 P	
Basal	p4EBP1	MFI	 281	(241	–	318)	 290	(241	–	343)	 0.011	
Max.	p4EBP1	MFI	 502	(424	–	571)	 550	(408	–	630)	 0.2	




	 HLA-DR+		 HLA-DR–		 P		
CD4+	p4EBP1	MFI	 528	(442	–	615)	 467	(401	–	529)	 <0.001	
CD8+	p4EBP1	MFI	 546	(420	–	629)	 536	(396	–	635)	 0.3	
Table	5.3.	Maximal	MTORC1	activity	according	to	activation	status.		














	 HIV	negative	 HIV	positive	 P	
Basal	CD4+	p4EBP1	MFI	 265	(239	–	318)	 300	(261	–	349)	 0.4	
Basal	CD8+	p4EBP1	MFI	 298	(242	–	364)	 273	(228	–	325)	 0.5	
Max.	CD4+	p4EBP1	MFI	 502	(434	–	563)	 510	(394	–	597)	 0.9	
Max.	CD8+	p4EBP1	MFI	 559	(421	–	617)	 491	(385	–	648)	 0.4	
CD4+	p4EBP1+	%	 49.5	(39.7	–	65.0)	 57.1	(48.6	–	64.8)	 0.4	





























	 Baseline		 Post		 P		
%	HLA-DR+	(CD4+)	 57.1	(42.7	–	72.4)	 46.0	(35.8	–	56.2)	 0.036	








	 Normal	 AA	placebo	 AA	 MM	placebo	 MM	
sCD14	/	mg.ml-1	 <4	 2.0	(1.5-2.5)	 1.8	(1.4-2.4)	 1.7	(1.4-2.2)	 2.0	(1.5-2.6)	
LPS	/	EU.ml-1	 <1	 173	(88-232)	 177	(104-264)	 161	(79-262)	 184	(107-262)	
CRP	/	mg.ml-1	 <5	 3.9	(1.1-9.7)	 1.8	(0.7-3.4)	 2.0	(0.9-8.5)	 2.0	(0.7-7.9)	
Table	5.6.	Serum	levels	of	sCD14,	LPS	and	CRP	at	baseline.	EU,	endotoxin	units.	
	None	of	the	interventions	had	any	effect	on	these	markers	(Table	5.7).	HIV	status	did	not	influence	the	response	to	supplementation	(data	not	shown).	CRP	was	weakly	correlated	with	sCD14	at	baseline	(ρ	0.26,	P	=	0.017)	and	in	all	intervention	groups	post-intervention	(ρ	0.31,	P	0.004	across	intervention	groups)	but	neither	were	correlated	with	LPS.		
Change	in	 AA	 Placebo	 P	 MM	 Placebo	 P	
LPS	(EU/ml)	 -36	(-136-86)	 -24	(-91-58)	 0.64	 -55	(-165-15)	 5	(-91-86)	 0.11	
CRP	(mg/l)	 0.05	(-0.8-1.7)	 -0.3	(-2.9-2.0)	 0.26	 0.06	(-0.8-2.5)	 -0.2	(-1.5-0.8)	 0.19	











	 HIV	negative	 HIV	positive	 P	
sCD14	/	ng.ml-1	 1.7	(1.4-2.0)	 2.5	(2.1-3.1)	 <0.001	
LPS	/	EU.ml-1	 175	(97-262)	 161	(91-266)	 0.9	








	 Increased	with	intervention	 Reduced	with	intervention	 Q2Y	 P	for	
model	
MM	v	placebo	 Panthothenate,	HMB,	PAGn,	4CS	 NMNA,	3HPHPA	 0.35	 0.01	
AA	v	placebo	 BAIBA,	PAGn,	4CS,	citrate	 No	significant	changes	 0.35	 0.01	







	 Increased	over	time	 Reduced	over	time	 	 Q2Y	 P	for	
model	
MM	pre	v	post	 Pantothenate,	HMB,	succinate,	2PY,	NMND	 BAIBA,	4HH,	3IS	 0.54	 0.01	
AA	pre	v	post	 Citrate,	myo-inositol,	formate	 Taurine,	glycolate,	trans-aconitate	 0.55	 0.01	
MM+AA	pre	v	post	 Pantothenate,	HMB,	succinate,	2PY,	PAGn,	citrate,	NMND,	unknown	 BAIBA,	2HIB,	choline,	acetylcholine,	taurine,	hippurate	 0.79	 0.01	





Outcome	 Positively	correlated	 Negatively	correlated	 P	for	model	
VH	 HMB,	DMG,	creatine,	creatinine,	GAA,	taurine,	2PY,	formate	 No	significant	changes	 0.01	




























PAGn	 Phe	 Co-metabolite	 Produced	by	hepatic	conjugation	of	L-Gln	with	microbially	derived	phenylacetic	acid.	Correlated	with	VH	in	childhood	EE.	 (Aronov	et	al.,	2011;	Farràs	et	al.,	2018)	
N-methylnicotinic	
acid	





HPHPA	 Phe	 Co-metabolite	 Microbially	derived	L-Phe	metabolite	–	particularly	Clostridia.	Possibly	implicated	in	neuropsychiatric	disorders.	 (Shaw,	2010;	Xiong	et	al.,	2016)	
β-amino-isobutyric	
acid	





2PY	 Trp	 Host	 Correlated	with	childhood	stunting.	 (Mayneris-Perxachs	et	al.,	2016)	
N-methyl-
nicotinamide	
NMND	 B3	/	Trp		/	IDO	 Host	 L-Trp	/	Niacin	(B3)	derivative.	Hgher	levels	associated	with	enhanced	catch-up	growth	in	childhood	undernutrition.	 (Mayneris-Perxachs	et	al.,	2016)	
2-hydroxy-
isobutyrate	
2HIB	 	 Co-metabolite	 Correlated	with	childhood	stunting	and	VH	in	childhood	EE.	 (Farràs	et	al.,	2018;	Mayneris-Perxachs	et	al.,	2016)	
Pantothenate	 	 B5	 Host	 Required	for	lipid	biosynthesis.	Correlated	with	childhood	stunting.	 (Mayneris-Perxachs	et	al.,	2016)	
	 172	
Taurine	 	 Cys	 Co-metabolite	 Low	levels	associated	with	childhood	stunting.	 (Semba	et	al.,	2016)	
4-cresyl	sulphate	 4CS	 Tyr	 Co-metabolite	 Correlated	with	childhood	stunting.	 (Mayneris-Perxachs	et	al.,	2016)	
Citrate	 	 TCA	 Host	 Negatively	correlated	with	childhood	stunting.	 (Mayneris-Perxachs	et	al.,	2016)	
Succinate	 	 TCA	 Host	 Correlated	with	VH	in	childhood	EE.	 (Farràs	et	al.,	2018)	
Fumarate	 	 TCA	 Host	 Unknown	 	
Myo-inositol	 	 PL	 Host	 Enhances	insulin	sensitivity.	Precursor	to	membrane	phospholipids.	 	
Formate	 	 	 Co-metabolite	 Byproduct	of	acetate	metabolism.	 	
Hippurate	 	 	 Co-metabolite	 Correlated	with	childhood	wasting	and	underweight.	 (Mayneris-Perxachs	et	al.,	2016)	
4-hydroxyhippurate	 	 	 Co-metabolite	 Correlated	with	VH	in	childhood	EE.	 (Farràs	et	al.,	2018)	
Glycolate	 	 	 	 Unknown	 	
Trans-aconitate	 	 TCA	 	 Unknown	 	
3-indoxyl	sulphate	 3IS	 Trp	 Co-metabolite	 Correlated	with	childhood	stunting	and	VH	in	childhood	EE.	 (Farràs	et	al.,	2018;	Mayneris-Perxachs	et	al.,	2016)	
Choline	 	 	 	 Required	for	lipid	membrane	stability	and	lipid	metabolism.	 	
Acetylcholine	 	 TCA	 	 Unknown	 	
Guanidinoacetic	
acid	







	 AA	 Placebo	 P	 MM	 Placebo	 P	
Baseline	GLP2	
(ng/mL)*	
0.76		(0.0	–	1.4)	 0.92		(0.49	–	1.4)	 0.44	 0.75		(0.0	–	1.5)	 0.88		(0.51	–	1.4)	 0.86	
Δ	GLP2	
(ng/mL)	




	 HIV	negative	 HIV	positive	 P	







	 AA	 Placebo	 MM	 Placebo	
MUAC	 27.3		(25.3	–	30.2)	 28.5		(25.8	–	32.0)	 28.3		(25.4	–	31.3)	 27.9		(25.4	–	31.3)	
Grip	strength	 31.8		(24.7	–	39.2)	 29.2		(27.1	–	36.9)	 30.7		(27.5	–	36.9)	 31.2		(25.7	–	37.9)	
Body	fat	%	 24.5		(17.2	–	34.4)	 30.9		(19.3	–	40.6)	 30.3		(17.6	–	38.1)	 28.5		(17.3	–	36.1)	
BMI	 22.5		(19.7	–	25.0)	 22.4		(20.5	–	27.6)	 23.0		(20.0	–	26.4)	 21.5		(19.8	–	25.8)	
Table	5.15.	Baseline	anthropometric	characteristics	by	intervention	group.		
Change	in:	 AA	 Placebo	 P		 MM	 Placebo	 P		
MUAC	 0.3		(-0.8	–	1.2)	 0.2		(-1.0	–	1.4)	 0.86	 0.1		(-0.8	–	1.4)	 0.3		(-1.0	–	1.0)	 0.79	
Grip	strength	 0.0		(-2.8	–	1.6)	 -0.9		(-3.8	–	1.1)	 0.25	 -0.9		(-3.8	–	1.3)	 -0.6		(-2.4	–	0.9)	 0.64	
Body	fat	%	 -1.2		(-3.4	–	0.7)	 -0.8		(-3.7	–	1.3)	 0.69	 -1.1		(-3.6	–	1.5)	 -0.9		(-3.5	–	0.6)	 0.89	





	 HIV	negative	 HIV	positive	 P		
MUAC	 28.0	(25.7	–	31.0)	 27.9	(25.1	–	32.0)	 0.90	
Grip	strength	 34.4	(27.0	–	39.1)	 28.7	(25.7	–	33.0)	 0.04	
Body	fat	%	 27.7	(16.9	–	36.2)	 31.7	(21.6	–	38.6)	 0.31	
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Amino acids and / or multiple Micronutrients in Adult Zambians with environmental Enteropathy: effects on intestinal 
structure & function and host-microbiome interactions. A randomised placebo controlled trial (AMAZE) 
 
We would like to invite you to be part of this research project. You should only agree to take part if you want to, it is entirely up to 
you. If you choose not to take part there won’t be any disadvantages for you and you will hear no more about it. Choosing not to 
take part will not affect your access to treatment or services in any way, now or in the future. 
 
Please read or listen to the following information carefully before you decide to take part; this will tell you why the research is 
being done and what you will be asked to do if you take part. Please ask if there is anything that is not clear or if you would like 
more information.  
 
If you decide to take part you will be asked to sign a consent form to say that you agree. You are still free to withdraw at any time 
and without giving a reason. 
 
Why we are doing this research 
Almost all children and adults who live in Misisi, like millions of other people in Africa and around the world who do not have 
easy access to clean water or toilets, often have problems with bowel inflammation. Although this inflammation doesn't cause any 
symptoms or make you feel unwell, we now think that it causes significant problems with growth and development. 
 
Over the last twenty years, we have done several research projects into this problem in Misisi, and we have learned a lot about this 
condition. Unfortunately, there is still a lot that is unknown, and there are still no treatments for the inflammation. 
 
Why we are doing this new research study 
One of our previous studies suggested that giving people some extra vitamins every day may help with some of the signs of the 
inflammation. It is also possible that the inflammation can be reduced by giving people some simple proteins to take. We would 
like to investigate the effects that these simple proteins and vitamins have on bowel inflammation in more detail. If the results are 
promising, then future trials will see if people should be given these supplements routinely. 
 
What the study involves 
You will be asked to take two supplements every day – either a vitamin pill or inactive pill, and either a simple protein powder or 
energy powder. You will take the same supplements every day for four months. You will not be able to tell which pill contains the 
vitamins, or which powder contains the proteins. Most people (three out of every four) will receive either the vitamins or the 
protein powder or both, but some people (one out of every four) will get the energy powder and inactive capsule. This is so that 
we can be sure that any benefits are truly due to the vitamins and / or proteins, rather than chance. Whether you get vitamins, 
protein, energy powder or inactive pill is up to pure chance, and you will not be told which substance you are getting. Even your 
doctors will not know until the end of the study. 
 
It is very important that you take the supplements every day, as this is the only way to be sure whether or not they will work. For 
this reason it is also very important that the supplements are only taken by you and not shared with or given to anyone else. 
Although the supplements are very safe in healthy adults, we do not know what their effects are in children, or in people that we 
have not assessed. 
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The supplements can be taken by themselves, or mixed into or sprinkled on top of nshima or water. It is important that you take all 
of the supplements every day. It is probably easiest for you to take them with your main meal, but you can take them at another 
time of day if you forget. 
 
 
The investigations you will have 
Before you enter the study, you will have a full medical assessment and examination. We will also ask for a stool sample to make 
sure you don't have a worm infection. If you do, we will give you treatment for this. 
 
If we identify any medical problems, we will give you treatment for this, or refer you to a specialist at UTH. 
 
We will bring you to UTH before you start and after you finish the supplements after four months. At UTH, we will examine the 
inside of your food pipe, stomach and start of your small bowel using a small flexible camera (endoscopy), and take some tiny 
tissue samples of the lining of your bowel at the same time. We will also take two blood samples (which is about half a mouthful), 
two urine samples, a saliva sample and a stool sample on the same day. Finally, we will do some specialist tests of body 
composition, to see how much of your body is made up of water, muscle and fat. All these tests are completely safe and painless. 
 
These tests will take most of a day and we will give you 80K to compensate you for the time you have given to come for them. 
 
 
About the endoscopy camera test 
The endoscopy test feels strange but is not painful. It is a very safe test. Professor Kelly and his team are very experienced and 
have performed over 2500 endoscopies on people from Misisi without any major problems. 
 
You will have the endoscopy test lying down on your side. You can keep your clothes on. We will give you some numbing spray 
to swallow and give you an injection to make you feel sleepy and relaxed. Many people fall asleep and can’t remember the test 
afterwards. The flexible camera is about as thick as your finger and so can be easily swallowed, although it will feel strange. We 
will take some tiny tissue samples of the lining of the bowel, which you won't feel as there is no sensation in this part of the 
bowel. The tissue samples are about the size of a small scratch, and are so small that they don't damage your bowel at all.  
 
Your stomach must be empty for the test to be done safely, so you can't have anything to eat or drink on the day of the endoscopy 
until after the procedure, but we will give you lunch afterwards. 
 




Effective medicine for HIV is now freely available in Zambia, and it is much more effective if discovered and treated before it 
gets advanced and causes symptoms. Knowing your HIV status is important for your health and the health of your family. It is 
therefore a good idea to have an HIV test regardless of whether or not you want to take part in the study, and whether or not you 
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feel unwell. To take part in the study, you will need to have an HIV blood test, because HIV can affect bowel inflammation and 
how it reacts to the supplements. If you are found to have HIV, we will refer you to specialists who will investigate you further 
and start treatment if you need it. 
 
The result of the HIV test is completely private and confidential. We are not allowed to tell your friends or family, or anyone else, 
what the result is without your permission, even if it is negative.  
 
 
Who can take part in the study 
Most adults who live in Misisi B section can take part. We cannot include children, women who are pregnant or breast feeding, or 
people who are unable to have an endoscopy test. 
 
 
What we do with your samples 
We only use the samples you provide for research. Any samples that we do not need for research will be destroyed. We have no 
need to use the samples you provide for any other purpose, including selling them or giving them to people who are not involved 
in the research. It is also against the law to do so. 
 
We do many of the research analysis in the laboratories at UTH. Some of the experiments will need to be done by Professor 
Kelly's research team in the UK, so some of your samples may be sent there. His team in the UK will also either use the samples 
for research, return them to Zambia, or destroy them. Like in Zambia, his UK team is not allowed to do anything with the samples 
that isn’t to do with research, including selling them or giving them to people who aren’t involved in the research. 
 
We do not use all the samples immediately, and we often have to store them for use in the future. Samples are normally stored in 
freezers which are kept securely in the laboratories, which only Professor Kelly and his team have access to. When we have 
completed all the experiments that we need for the study, we will see if any samples are left over. If so, we would like to keep 
them for use in future research studies, so that we may not need to repeat the procedures to get more samples. The same rules on 
what we can do with the samples, and who can use them, will apply in any future research. Before we could use your samples for 
research in the future, we would first need to ask permission from the Ethics Committee in the University of Zambia who will 
make sure that it is ethical to do so. 
 
We do many different experiments on the samples you provide, and if you are interested we can demonstrate and explain some of 
these to you, including how the samples are stored. 
 
 
What we do with the information you provide 
During the research we collect information about you, for example how much you weigh, how old you are and how much 
inflammation is in your bowel. We store the information on computers and remove your name and other ways of identifying you, 
so that there is no way of telling who the information refers to. The only way we can find out is by looking up your research 
number in a book which is kept in a locked office at UTH, which only Professor Kelly has access to. The researchers who analyse 
your samples will not be able to tell whose samples they are analysing. 
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Any and all information you give us is confidential. This means that we are not allowed to tell anyone about you, even if they are 
friends or family. When the information we collect is analysed, it becomes impossible to tell who gave the samples, so it is not 
possible for you to be identified from your samples. 
 
We think that the knowledge we gain in this study will give us a lot of important information into what causes the bowel 
inflammation and what can be done about it. We would like to share this information with other scientists and governments in 
conferences and publications. Nobody who hears or reads about the research will be able to tell that the information or samples 
came from you. 
 
How this study might benefit you 
While you are in the study, you and your family will have free health care at the Misisi clinic. If you have an illness that we 
cannot treat at the clinic, we will send you for further tests or treatment by specialists at UTH, which you will not have to pay for. 
 
The camera endoscopy test is the best test for examining your food pipe and stomach. Sometimes people have problems like 
ulcers that don't cause any symptoms, but which can sometimes still be serious. If we find that you have any of these problems 
when we do the endoscopy camera test we will investigate and treat them. 
 
It is important for your health and the health of your family that you know your HIV status, even if you feel completely well. 
Effective medicine for HIV is now freely available in Zambia, and it is much more effective if discovered and treated before it 
gets advanced. 
 
Insurance and what to do if you have questions or concerns 
Queen Mary University of London has agreed that if you are harmed as a result of your participation in the study, you will be 
compensated, provided that, on the balance of probabilities, an injury was caused as a direct result of the intervention or 
procedures you received during the course of the study. These special compensation arrangements apply where an injury is caused 
to you that would not have occurred if you were not in the trial. These arrangements do not affect your right to pursue a claim 
through legal action. 
 
It is up to you to decide whether or not to take part. If you do decide to take part you will be given this information sheet to keep 
and be asked to sign a consent form.  
 
If you have any questions or concerns about the study or how it is conducted, you can contact Professor Kelly's team in the Misisi 
clinic at any point. If you are not happy to do this, or are not happy with the advice you get from Professor Kelly's team, you can 
contact the University of Zambia Biomedical Research Ethics Committee, University of Zambia School of Medicine Ridgeway 




 v.2.1 / 27th Feb 2015 
Consent form (English) 
 
Please complete this form after you have read or listened to the Information Sheet and/or listened to an explanation about 
the research. 
 
Amino acids and / or multiple Micronutrients in Adult Zambians with environmental Enteropathy: effects on 
intestinal structure & function and host-microbiome interactions. A randomised placebo controlled trial. (AMAZE) 
 
UNZABREC reference: 007-11-14 
 
1. I have read or listened to the Participant Information Sheet for this study (version 2.1, dated 18th December 2014). 
2. The research has been explained to me. I understand what the research involves and what is required of me. 
3. I understand that I will have a blood test for HIV. 
4. I understand that samples I provide may be sent abroad for research purposes only, and that after use the 
samples will either be returned to Zambia for storage or destroyed. 
5. I consent to the long term storage of any samples I provide (including blood, urine, stool, small bowel fluid and 
endoscopic biopsies) in secure facilities at the University of Zambia after this research study has finished, for 
possible ethically approved research projects in the future. 
6. I understand that there is no obligation for me to participate in the research, and that I do not have to give a 
reason for not participating. 
7. I understand that if I decide at any time during the research that I no longer wish to participate, I can notify the 
researchers involved and be withdrawn from it immediately, without giving a reason. 
8. I consent to the processing of my personal information for the purposes of this research study. I understand that 
such information will be treated as strictly confidential at all times and that any identifiable information about me 
will be available only to members of the study team. 
 
 
Participant’s Statement:  
 
I ___________________________________________ have read or listened to statements 1-8 above and I agree to 
take part in the study. 
 
Signed:      Date:  
 
Witnessed:     Date: 
 
 
Investigator’s Statement:  
 
I ___________________________________________ confirm that I have carefully explained the nature, demands and 
any foreseeable risks of the proposed research to the volunteer. 
 
Signed:      Date:  
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Name ____________________________________________________________________ 
House number B __ __ __ 
Date __ __ / __ __ / __ __ (dd/mm/yy) 
 
 
Inclusion criteria (TICK IF CRITERIA MET) 
c AGED BETWEEN 18 AND 60 YEARS 
c ABLE TO GIVE INFORMED CONSENT 
c RESIDENT IN MISISI STUDY AREA 
 
 
Exclusion criteria (TICK IF CRITERIA MET THEN DO NOT RECRUIT) 
c NOT WILLING TO UNDERGO HIV TEST 
c WARFARIN OR BLEEDING DISORDER 
c UNABLE TO HAVE ENDOSCOPY SAFELY 
c PREGNANT OR BREAST FEEDING 
c BMI < 18 
c UNWILLING TO CONSENT FOR LONG TERM STORAGE OF SAMPLES 
 
 
Temporary exclusion criteria (POSTPONE FURTHER INVESTIGATIONS UNTIL CRITERIA NO LONGER APPLY) 
c DIARRHOEA IN THE LAST 4 WEEKS (>3 WATERY STOOLS FOR >24 HOURS) 
c USED ANTIBIOTICS OR NSAIDs WITHIN LAST 4 WEEKS (TAKEN REGULARLY FOR >72 HOURS) 
c HELMINTH / WORM INFECTION 
 
 
Date eligible to start study (if not today) __ __ / __ __ / __ __ 
4 WEEKS AFTER LAST LOOSE STOOL 
4 WEEKS AFTER LAST ANTIBIOTIC OR NSAID USE 
6 MONTHS AFTER FINISHED ANTI-HELMINTHIC COURSE 
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Demographics and social history 
Age   ___ ___ years      Sex  Male  /  Female  
Occupation  ____________________________________  Time in Misisi  ___ ___ years 
Marital status   Single  /  Married  /  Widowed  /  Divorced  /  Separated  /  Co-habiting  
Smoking  Never  /  Ex  /  Rarely  /  Weekly  /  Daily  
   Year started ___ ___ ___ ___ / Year stopped ___ ___ ___ ___ 
Alcohol  Never  /  Monthly or less  /  2-3 times a month  /  Weekly  /  2-3 times a week  /  Daily 
Alco drink  Beer  /  Kachasu  /  Other  __________________ 
Level of education None  /  Primary  /  Secondary  /  College  /  University  
 
Household characteristics 
Does someone in your household own the house you live in? No  / Yes  
Do you have electricity?   No  / Yes  
Do you have a radio?    No  / Yes  
Do you have a cell phone?    No  / Yes  
Do you have any pets which live indoors? No  / Yes  
 
How often do you… 
Boil water  Never  /  Cholera  /  Rains  /  Most days  /  Always  
Add chlorine  Never  /  Cholera  /  Rains  /  Most days  /  Always  
 
Household hygiene score 
Cleanliness  0 / 1 / 2 
Water storage  0 / 1 / 2 
Food storage  0 / 1 / 2 
Hand washing  0 / 1 / 2 
Sanitation  0 / 1 / 2   HHS total  ___ ___ / 10
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Please complete food frequency questionnaire for last month (see separate sheet) 
 
Past medical history          Year diagnosed (yyyy) 
HIV status  Negative  / Positive  / Unknown   __ __ __ __ 
TB No  /  Pulmonary  /  Abdominal  /  Meningitis  /  Other  __________________ __ __ __ __ 
Hepatitis / jaundice No  / Yes          __ __ __ __ 
Stroke   No  / Yes         __ __ __ __ 
Surgery  No  / Yes  _____________________________________  __ __ __ __ 
Diabetes  No  /  Diet controlled  /  Tablet  /  Insulin  /  Both    __ __ __ __ 
Heart disease  No  /  MI  /  Heart failure  /  Other  _______________  __ __ __ __ 
Hypertension  No  /  Yes         __ __ __ __ 
Asthma  No  /  Yes – no admissions  /  Yes – previous admissions   __ __ __ __  
 
Other major illness 1 _____________________________________________ __ __ __ __  
Other major illness 2 _____________________________________________ __ __ __ __  
Other major illness 3 _____________________________________________ __ __ __ __  
 
Current symptoms 
Current symptom 1 _________________________________ Duration 1  (days) __ __ / (weeks) __ __ 
Current symptom 2 _________________________________ Duration 2  (days) __ __ / (weeks) __ __  
Current symptom 3 _________________________________ Duration 3  (days) __ __ / (weeks) __ __ 
 
Current medications         Year started (yyyy) 
Drug 1 ______________________ Dose 1___________ prn / od / bd / tds / qds __ __ __ __  
Drug 2 ______________________ Dose 2___________ prn / od / bd / tds / qds __ __ __ __  
Drug 3 ______________________ Dose 3___________ prn / od / bd / tds / qds __ __ __ __  
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Antihypertensives No   / Yes       __ __ __ __  
Heart failure  No   / Yes       __ __ __ __  
Diabetes  No   / Tablets  /      Insulin      /    Both  __ __ __ __  
ART   No   / Yes       __ __ __ __  
Aspirin  No   / Yes       __ __ __ __  
Asthma  No   / Yes       __ __ __ __ 
Other ___________________________ Indication ________________________ __ __ __ __  
 
Do you take any unprescribed / self-prescribed / over-the-counter / traditional medicines? 
No   / Yes  ____________________________________________________________ 
 
Observations 
Height  __ __ __ cm    HR  __ __ __ 
Weight  __ __ . __ kg    BP  __ __ __ / __ __ __ 
MUAC  __ __ . __ cm     RR  __ __ 
Karnofsky ___ ___ ___ / 100   Grip strength __ __ . __ kg  LEFT  /  RIGHT 
            (TEST NON-DOMINANT SIDE)
  
Physical examination (CIRCLE ALL THAT APPLY) 
Breathlessness None   / After exertion   /  At rest  
Lymphadenopathy None   / Cervical      /     Axillary      /     Inguinal      /     Multiple  
Skin & hair  Normal   /  Pellagra   /  Silky hair   /  Keloid  
Jaundice / Pallor / Oedema / Clubbing / Cyanosis / Goitre 
BCG scar / Smallpox jab scar  
Oral candida / Oral KS 
Other  _________________________________________________________________________________ 
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CVS Normal  / Abnormal  ______________________________________________ 
 Signs of rheumatic heart disease / Signs of LVF  / Signs of RVF 
RS Normal  / Abnormal  ______________________________________________ 
 Wheeze / Fibrosis / Effusion / Consolidation  
GI Normal  / Abnormal  ______________________________________________ 
 Surgical scars    /    Hepatomegaly    /    Splenomegaly    /    Palpable kidneys    /    Mass    /    Ascites 
Peripheral neuropathy No  / Yes  




Date of test __ __ / __ __ / __ __ (dd/mm/yy) 
Negative  / Positive    CD4 count (if positive) __ __ __ 
 
Stool  
Date of test __ __ / __ __ / __ __ (dd/mm/yy) 
Result  Negative  / Asc.  / Strong.  / Enterobius  / Taenia  / Schisto.  / Trich.  / Hook.   
Other  _______________________ 
Treatment Albendazole  / Mebendazole  / Praziquantel  / Other  _______________________ 




Date ___ ___ / ___ ___ / ___ ___ Pre   /   Post   /   Control ID ___ ___ ___ ___ 
 
 
TROPGAN AMAZE study: Endoscopy visit case report form 
Confocal laser endomicroscopy  Y / N   Settings           (Default)  
Pethidine (mg)  0 / 25 / 50 /   ____ Gamma __ . __ __  (1.74) 
Diazepam (mg)  0 / 5 / 7.5 /   ____ Bright __ . __ __ (0.47)  
Midazolam (mg)  0 / 2.5 / 5 /   ____  Laser __ __ __ (380) 
Buscopan (mg)  0 / 10 / 20    Operator PK   /   JLA 
 
Indication (controls only) Dysphagia | GORD | Dyspepsia/Abdo pain | Wt loss | Abn. radiology | Planned rpt |  
Other ________________________________________________________ 
 
Oesophagus Not seen / Normal / Stricture / Candida / Varices / Cancer / Ulcer / Other _______________ 
  Passable / Impassable (if relevant)     Benign / Malignant (if relevant) 
Stomach  Not seen / Normal / Varices / Cancer / GU / Gastritis / Pyloric stenosis / Other ___________ 
  Passable / Impassable (if relevant)     Benign / Malignant (if relevant) 
Duodenum Not seen / Normal / Stricture / DU / Duodenitis / Other _______________________________ 
  Passable / Impassable (if relevant) 
 
iScan grade   Normal  /  Leaves  /  Ridges  /  Convolutions  /  Atrophic  
Micro grade  Normal  /  Leaves  /  Ridges  /  Convolutions  /  Atrophic  
 
Timings checklist     Intubation depth <D1/2 | D1/2 | D2 | D2/3 | D3 | >D3 
c Baseline blood ___ ___ : ___ ___ 
c Baseline urine  ___ ___ : ___ ___ 
c Fluorescein  ___ ___ : ___ ___ 
c Biopsies  ___ ___ : ___ ___ 
c Solutions  ___ ___ : ___ ___ 
c 3h blood  ___ ___ : ___ ___ 
c 3h urine   ___ ___ : ___ ___ 
c Digest started  ___ ___ : ___ ___   ADVERSE EVENTS / NOTES: PTO 
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Grip strength   Y / N  ____ ____ . ____ kg 
 
BodPod   Y / N 
 







TROPGAN AMAZE study: Monthly follow-up case report form     ID ___ ___ ___ ___ 
Date ___ ___ / ___ ___ / ___ ___ (dd/mm/yy)   Study week number 4 8 12 End 
 
Weight (end-of-study visit only) ___ ___ ___ . ___ kg  MUAC (end-of-study visit only) ___ ___ . ___ cm 
 
MM tabs remaining   ____ ____    AA packets remaining   ____ ____ 
How easy is it for you to remember to take both your medicines every day? Very easy | Quite easy | Quite difficult | Very difficult 
How easy is it for you to take all your medicines? Very easy | Quite easy | Quite difficult | Very difficult 
How often have you forgotten to take your medicines? 
Most days | 2 or 3 times a week | About once a week | Less than once a week | Once or twice | Never 
Describe any side effects ______________________________________________________________________________________ 
Describe any problems with taking the medicines _________________________________________________________________ 
 
In the last month (since your last visit) have you had... 
Diarrhoea (liquid stool at least 3 times a day) No  | Yes  
 How long did it last?   3 days or less | More than three days 
 Was there blood?   No  | Yes  
Time off your usual activities?  No  | Yes  
 Treatment given    None | ORS | Abx (self-prescribed) | Abx (clinic/hospital) | Admitted | Other 
 
Any other symptoms / illnesses No  | Yes  
 Details   _______________________________________________________________________________ 
 Treatment given  _______________________________________________________________________________ 
 Medical attention None | St Lawrence or other clinic (not admitted) | Admitted 
 
In the last month (since your last visit) have you taken... 
Antibiotics / antimalarials No  | Yes  
 Name   _____________________________________ | Unknown  
 For how many days? 1 | 2-3 | Up to a week | More than a week 
 Prescriber  Self | Clinic/hospital 
 Indication  Fever | Cough | Diarrhoea | Malaria (no blood tests) | Malaria (confirmed with tests) | Other 
 Details   _______________________________________________________________________________ 
 
Pain killers No | Paracetamol | Ibuprofen | Diclofenac | Indomethacin | Other_____________________ | Unknown 
 For how many days? 1 | 2-3 | Up to a week | More than a week 
 Prescriber  Self | Clinic/hospital 
 
Have you taken any other medicines or remedies (apart from your regular medicines)? No | Yes 
Details   _______________________________________________________________________________ 
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Related to study? 
 Definitely /  Probably /  Possibly  /  Remote / Not 
SAE? 





//Morphometry of intestinal biopsy sections v1 (C) 2016 John Louis-
Auguste (j.l.auguste@qmul.ac.uk) 
 
//.csv results file headings: 
//Base length ('B') = 'Perim.' or 'Length' 
//Villus area ('VA/VP') = 'Area' 
//Villus perimeter ('VA/VP') = 'Perim.' [base length needs to be 
subtracted from this value] 
//Villus height ('VH/VW') = 'Width' 
//Villus width ('VH/VW') = 'Height' 
//Muscularis mucosae length ('MM') = 'Perim.' or 'Length' 
//Crypt depth ('CD') = 'Perim.' or 'Length' 
//All other values should be ignored / deleted 
 
run("Open..."); 
//run("Enhance Contrast...", "saturated=5"); 
run("8-bit"); 
run("Set Scale...", "distance=1.1 known=1 pixel=1 unit=um global"); 
//Sets scale for 10X objective 
run("Set Measurements...", "area perimeter bounding display 
redirect=None decimal=3"); 
run("Colors...", "foreground=black background=white selection=red");  
run("8-bit"); //Converts to 8-bit image for thresholding 
rename(File.nameWithoutExtension); 
 
//Select all villi to be measured as a group on duplicated 8-bit image 
run("Select All"); 
run("Copy"); 
newImage(File.nameWithoutExtension, "8-bit white", 1680, 1056, 1); 
run("Paste"); 




waitForUser("Draw round all villi to be measured (double click to 
complete) then press OK. Draw across villus bases accurately!");  
run("Make Inverse");  
run("Cut"); //Leaves villi only 
 
//Define function to rename last RoI and leave it selected 
function roiRenameLast(name) { 





//Draw and measure all bases first 
var n = 0 
run("Select None"); 
while (getBoolean("Draw a villus base?") == 1) { 
 setTool("polyline"); 
 run("Line Width...", "line=5"); 
 waitForUser("Draw villus base (double click to start & complete) 
then press OK"); 
 roiManager("Add"); 
 n++; 
 roiRenameLast(" B"+n); 
 roiManager("Measure"); 
 setForegroundColor(0, 0, 0); 
 run("Fill", "slice"); 
} 
 




//Threshold villi for automated measurements 
run("Auto Threshold", "method=Default white"); 
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setTool("wand"); 
waitForUser("Check thresholding by clicking on each villus in turn. 
Correct defects etc. using PENCIL TOOL then press OK. [F1 or Edit-
>Options->Colors...->'Foreground': white=delete / black=draw]");  
 
//VP, VA, VH, VW measurements for each villus 
n=0; 
while (getBoolean("Measure villus parameters?") == 1) { 
 run("Select None"); 
 setTool("wand"); 
 waitForUser("VA/VP measurement: Click on a villus then press OK. 
Ensure correct villus perimeter is outlined in red."); 
 roiManager("Add"); 
 n++; 
 roiRenameLast(" VA/VP"+n); 
 roiManager("Measure"); 
 setTool("polyline"); 
 run("Line Width...", "line=500"); 
 waitForUser("VH/VW measurement (1/3): Draw villus long axis 
(double click to start & complete) then press OK"); 
 run("Straighten..."); 
 setTool("wand"); 
 waitForUser("VH/VW measurement (2/3): Click on selected villus 
then press OK. Ensure correct villus perimeter is outlined in red."); 
 run("To Bounding Box"); 
 waitForUser("VH/VW measurement (3/3): Adjust bounding box if 
required, then press OK"); 
 rename(File.nameWithoutExtension); 
 roiManager("Add"); 
 roiRenameLast(" VH/VW"+n); 
 roiManager("Measure"); 
 roiManager("Delete"); 
 run("Close"); //Closes bounding box image 
 } 
 
run("Close"); //Closes thresholded image 
 
//Draw MM 
roiManager("Show All"); //Shows all measured villi for assessing MM 
setTool("polyLine"); 
run("Line Width...", "line=1"); 







while (getBoolean("Draw crypt?") == 1) { 
 setTool("polyline"); 
 run("Line Width...", "line=1"); 








//Save 8-bit image with overlays, save results as csv, tidy up 
roiManager("Show All"); 
run("Line Width...", "line=1"); 
run("Flatten"); 
rename(File.nameWithoutExtension+"_overlay"); 
saveAs("tiff"); // Use saveAs(format, path) to save to specific 
directory 
saveAs("results"); // Use saveAs(format, path) to save to specific 
directory 
selectWindow("ROI Manager"); 
run("Close"); 
run("Close All"); 
runMacro("/Applications/Fiji.app/macros/AutoRun/Morpho.ijm"); 
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Appendix	5.	Incubation	media	for	MTORC1	flow	cytometry	assay.	 	
	
	
	
	
	
	
	
	
	
	
	
	
	
										
Table	S1.	In	addition,	RPMI	in	the	nutrient	rich	solution	contains	a	number	of	vitamins,	and	
both	solutions	contained	balanced	inorganic	chloride,	phosphate,	bicarbonate	salt	solutions	
(calcium,	magnesium,	potassium,	sodium).		
		 Nutrient	deprived	 Nutrient	rich	
FBS	(lot	specific)	 –	 10%	
Glucose	 5.56mM	 11.11mM	
L-Glutamine	 1mM	 4mM	
L-Glycine	 –	 0.13mM	
L-Arginine	 –	 1.15mM	
L-Asparagine	 –	 0.38mM	
L-Aspartic	acid	 –	 0.15mM	
L-Cysteine	 –	 0.21mM	
L-Glutamic	acid	 –	 0.14mM	
L-Histidine	 –	 0.10mM	
L-Hydroxyproline	 –	 0.15mM	
L-Isoleucine	 –	 0.38mM	
L-Leucine	 –	 0.38mM	
L-Lysine	 –	 0.22mM	
L-Methionine	 –	 0.10mM	
L-Phenylalanine	 –	 0.09mM	
L-Proline	 –	 0.17mM	
L-Serine	 –	 0.29mM	
L-Threonine	 –	 0.17mM	
L-Tryptophan	 –	 0.02mM	
L-Tyrosine	 –	 0.11mM	
L-Valine	 –	 0.17mM	
Gentamicin	 50μg/mL	 50μg/mL	
Penicillin	G	 100U/mL	 100U/mL	
Streptomycin	 100mg/mL	 100mg/mL	
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